BIOD reverse split. ZIOP initiates Phase 3 SCLC trial. BPAX plans further LibiGel trials + AVNR PLX news

Jun 12, 2012 No Comments by

Biodel Inc. (Nasdaq:BIOD) announced that it will effect a one-for-four reverse split prior to the start of trading on June 12, 2012. The number of authorized shares of common stock will be adjusted to 25m.

ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced that has initiated its Phase 3 MATISSE study (Multicenter Adaptive Trial Investigating Small cell lung cancer Survival Endpoints), of palifosfamide for the treatment of small cell lung cancer.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced that it plans to initiate two new LibiGel Phase 3 efficacy trials for the treatment of female sexual dysfunction (FSD).It intends to apply for Special Protocol Assessment (SPA). LibiGel was shown to be not effective following the release of Phase 3 data in December 2012. However, the company argues that this was due to a greater than expected placebo response. BioSante also intends to continue the on-going LibiGel Phase 3 cardiovascular and breast cancer safety study as per protocol, with primary analysis of the safety study due in 2H 2012.

Avanir Pharmaceuticals, Inc(NASDAQ: AVNR) said that it plans to initiate a Phase 2 study of AVP-923 for the treatment of agitation in patients with Alzheimer’s disease (AD) during 3Q 2012.

Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced that it has received a $25m milestone payment from Pfizer Inc. as part of the companies’ global commercial agreement for ELELYSO (taliglucerase alfa).

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “BIOD reverse split. ZIOP initiates Phase 3 SCLC trial. BPAX plans further LibiGel trials + AVNR PLX news”

Leave a Reply